Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,728.50
Bid: 1,727.00
Ask: 1,728.00
Change: 23.50 (1.38%)
Spread: 1.00 (0.058%)
Open: 1,705.00
High: 1,729.50
Low: 1,695.50
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bribery serves as life-support for Chinese hospitals

Tue, 23rd Jul 2013 21:00

* Low salaries foster widespread bribery in public hospitals

* State fixes cost of hospital operations and caps drugprices

* Leaves public hospitals with little room to top updoctors' pay

* Britain's GlaxoSmithKline embroiled in bribery scandal

By Kazunori Takada

SHANGHAI, July 24 (Reuters) - Bribery is the lubricant thathelps keep China's public hospitals running, and the healthsystem would struggle to function without illegal payments topoorly paid doctors and administrators, say medicalpractitioners and industry experts.

They say government policies are partly to blame for asystem in which doctors and other staff expect to be paid extrafees to perform operations and take kickbacks frompharmaceutical firms and medical-equipment suppliers.

The profession's ugly underbelly was exposed last week whenpolice accused British drugmaker GlaxoSmithKline ofbribing officials and doctors for six years to boost sales andthe price of its medicines. GSK has called the developments"shameful" and on Monday said some of its Chinese executivesappeared to have broken the law.

China is an appealing market for pharmaceutical firms andmedical-equipment makers, with spending in the industry expectedto nearly triple to $1 trillion by 2020 from $357 billion in2011, according to consulting firm McKinsey.

The corruption stems largely from doctors' low basesalaries, which are set in line with a pay scale for governmentworkers. Hospitals can pay bonuses but, given public hospitalsare strapped for cash, compensation is usually low, say doctorsand industry experts.

A doctor fresh out of medical school in Beijing earns about3,000 yuan ($490) a month including bonuses -- roughly the sameas a taxi driver. A doctor with 10 years experience makes around10,000 yuan a month, according to Peter Chen, chief executive ofprivately run Oasis International Hospital in Beijing.

"Without the grey income, doctors would not have theincentive to practise," said Yanzhong Huang, a senior fellow forglobal health at the Council on Foreign Relations in New York.

CAN'T SURVIVE ON SALARIES

Over the past 30 years the Chinese government has made itshealthcare sector more market-oriented. That means the country's 13,500 public hospitals have to balance their own books.

Medical services accounted for just over 50 percent ofpublic hospital revenue in 2011, according to Health Ministrydata. About 40 percent came from prescribing drugs while therest was from other income as well as government subsidies,which have fallen steadily since the 1980s.

Hospital administrators can set fees for in-patient care,nursing and laboratory tests. But the state fixes the cost ofoperations to make surgery affordable to ordinary Chinese. Andit effectively caps the cost of many prescribed medicines bysetting a suggested price.

That leaves hospitals little room to top up wages.

One Chinese doctor who used to hold a senior position at aprominent hospital in Beijing said 80 percent of his income camefrom bribes. Without it, he would have earned less than $600 amonth, said the doctor, who left China five years ago to live inBritain where he continues practising medicine.

"These sums (bribes) are essential. You cannot survive onyour salary," said the 50-year-old physician, who spoke oncondition of anonymity due to the sensitivity of the issue.

An industry executive who has worked in China's medicalsector for more than 15 years said bribery and corruptionpermeated every level of a public hospital.

"They are seen as necessities in the current healthcaresystem," said the executive, who also declined to be identified.

The Health Ministry did not respond to a request forcomment. Officials at the National Development and ReformCommission, which sets the prices of prescribed medicines, alsodeclined to comment.

Low base salaries are a legacy of China's planned economy,said Jia Xijin, associate professor at the School of PublicPolicy and Management at Tsinghua University in Beijing,explaining the dilemma faced by the government.

China has also committed to making health care affordablefor its 1.37 billion people. The government has spent 2.2trillion yuan ($358 billion) on the system since 2009, of whichmore than 680 billion yuan was to provide universal healthinsurance coverage, state media quoted the Finance Ministry assaying earlier this year.

RED ENVELOPES

Public hospitals say recruiting new doctors is gettingharder as many physicians are turned off by the wages at a timewhen patient numbers are growing. Health Ministry data showedthe overall number of doctors rose 13 percent from 2008 to 2011,while patient visits jumped 28 percent.

"There will be no doctors left to treat the current doctorswhen they retire," said the accounting director at a Shanghaihospital who declined to be identified because she was notauthorised to speak to the media.

Low salaries have also spawned a system of under-the-tablepayments from patients. The payments are known as "hongbao" -- areference to the cash-filled red envelopes given as presentsduring Lunar New Year festivities -- and cover various servicesfrom jumping the queue for appointments to extra surgical fees.

Bob Wang, a 35-year-old businessman in Beijing, said he gavethe main surgeon who operated on his aunt's femur bonetransplant last year 5,000 yuan in "hongbao" on top of the100,000 yuan he paid to the hospital because he was worried thedoctor would not take the operation seriously otherwise.

There was unstated "hongbao" guidance for each type ofsurgery, he said.

"If my family or myself get sick ... we won't just go to thehospital. Everything will take forever -- from registration towaiting for a bed, to getting seen by a doctor to queuing forsurgery," he said.

According to the doctor now living in Britain, patients andtheir families could sometimes spend two to three times morethan the actual fee in "hongbao".

Critics doubt that an anti-corruption campaign by PresidentXi Jinping will have much impact.

Indeed, a former doctor at a major heart hospital in Beijingsaid eradicating corruption would be nearly impossible.

"It would be easy to find out who was taking money if thegovernment wanted to," said the cardiologist, who has beenworking in the United States since 2009.

"But everyone would be found guilty. How could the hospitalssurvive?"

More News
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 19:02

Moderna says it hit its 2023 COVID vaccine sales goal

Jan 8 (Reuters) - Moderna on Monday said its 2023 COVID vaccine sales would be around $6.7 billion, coming in above the lower end of its full-year forecast, and reiterated its goal of returning to sales growth in 2025.

Read more
4 Jan 2024 14:01

UK dividends calendar - next 7 days

Friday 5 January 
British Land Co PLCdividend payment date
Hill & Smith PLCdividend payment date
JD Sports Fashion PLCdividend payment date
JPMorgan Global Growth & Income PLCdividend payment date
Liontrust Asset Management PLCdividend payment date
Lok'n Store Group PLCdividend payment date
Real Estate Credit Investments Ltddividend payment date
RS Group PLCdividend payment date
Tate & Lyle PLCdividend payment date
Monday 8 January 
abrdn Equity Income Trust PLCdividend payment date
Intermediate Capital Group PLCdividend payment date
Tuesday 9 January 
no events scheduled 
Wednesday 10 January 
Assura PLCdividend payment date
Bellway PLCdividend payment date
Fidelity Special Values PLCdividend payment date
LXi REIT PLCdividend payment date
Severn Trent PLCdividend payment date
Volex PLCdividend payment date
Vp PLCdividend payment date
Thursday 11 January 
AJ Bell PLCex-dividend payment date
Ashtead Group PLCex-dividend payment date
BlackRock Latin American Investment Trust PLCex-dividend payment date
CMC Markets PLCdividend payment date
dotdigital Group PLCex-dividend payment date
Ecora Resources PLCex-dividend payment date
European Assets Trust PLCex-dividend payment date
Foresight Group Holdings Ltdex-dividend payment date
GSK PLCdividend payment date
ICG-Longbow Senior Secured UK Property Debt Investments Ltdex-dividend payment date
JPMorgan Asia Growth & Income PLCex-dividend payment date
Keystone Positive Change Investment Trust PLCex-dividend payment date
LondonMetric Property PLCdividend payment date
Murray International Trust PLCex-dividend payment date
National Grid PLCdividend payment date
Primary Health Properties PLCex-dividend payment date
Sage Group PLCex-dividend payment date
Smiths News PLCex-dividend payment date
SSE PLCex-dividend payment date
Supermarket Income REIT PLCex-dividend payment date
TR Property Investment Trust PLCdividend payment date
Walker Crips Group PLCex-dividend payment date
WH Smith PLCex-dividend payment date
Worldwide Healthcare Trust PLCdividend payment date
XPS Pensions Group PLCex-dividend payment date
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.